Loading
Lung Cancer Treatments and Mutations / RNA Interference and Gene Delivery · Journal article
Molecular Therapy — Nucleic Acids · September 5, 2026
The material analysed did not support any firm read.
This is a commentary on an emerging approach to engineer microRNAs (miR-129) incorporating gemcitabine as a multimodal therapeutic strategy for EGFR-mutant NSCLC with acquired TKI resistance. The source describes the rationale and concept without reporting efficacy, safety, or mechanistic data from the referenced work.
Journal article. Patients with EGFR-mutant non-small cell lung cancer (NSCLC) with acquired resistance to EGFR tyrosine kinase inhibitors.
EGFR-TKI resistance in NSCLC arises through diverse genetic and non-genetic mechanisms, creating therapeutic heterogeneity Proposed strategy incorporates nucleoside analog gemcitabine directly into tumor-suppressive miR-129
Source is a commentary, not a primary research report; no empirical data, efficacy measures, or safety outcomes are provided Actual efficacy and safety of the engineered miR-129–gemcitabine construct are not described in this source
This commentary frames a novel conceptual approach to overcome TKI resistance in EGFR-mutant NSCLC but does not provide evidence of clinical efficacy or safety; the referenced primary work by Intriago and colleagues would be needed to evaluate therapeutic potential.
This is a commentary describing a novel preclinical approach to engineer microRNAs as cancer therapeutics; it reports no original experimental data, effect sizes, or clinical outcomes.
This commentary frames a novel conceptual approach to overcome TKI resistance in EGFR-mutant NSCLC but does not provide evidence of clinical efficacy or safety; the referenced primary work by Intriago and colleagues would be needed to evaluate therapeutic potential.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
Resistance to systemic therapy remains a major challenge in non-small cell lung cancer (NSCLC). Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have improved outcomes for patients with EGFR-mutant tumors, but acquired resistance is common and can arise through diverse genetic and non-genetic mechanisms.1 This heterogeneity makes resistance difficult to address by targeting a single downstream pathway. In the previous issue of Molecular Therapy Nucleic Acids, Intriago and colleagues report a different approach by incorporating the nucleoside analog gemcitabine directly into the tumor-suppressive microRNA (miRNA) miR-129 (Figure 1).
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.